Literature DB >> 11042185

The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation.

X S Chen1, C D Funk.   

Abstract

5-Lipoxygenase is the key enzyme in the formation of leukotrienes, which are potent lipid mediators of asthma pathophysiology. This enzyme translocates to the nuclear envelope in a calcium-dependent manner for leukotriene biosynthesis. Eight green fluorescent protein (GFP)-lipoxygenase constructs, representing the major human and mouse enzymes within this family, were constructed and their cDNAs transfected into human embryonic kidney 293 cells. Of these eight lipoxygenases, only the 5-lipoxygenase was clearly nuclear localized and translocated to the nuclear envelope upon stimulation with the calcium ionophore. The N-terminal "beta -barrel" domain of 5-lipoxygenase, but not the catalytic domain, was necessary and sufficient for nuclear envelope translocation. The GFP-N-terminal 5-lipoxygenase domain translocated faster than GFP-5-lipoxygenase. beta-Barrel/catalytic domain chimeras with 12- and 15-lipoxygenase indicated that only the N-terminal domain of 5-lipoxygenase could carry out this translocation function. Mutations of iron atom binding ligands (His550 or deletion of C-terminal isoleucine) that disrupt nuclear localization do not alter translocation capacity indicating distinct determinants of nuclear localization and translocation. Moreover, data show that GFP-5-lipoxygenase beta-barrel containing constructs can translocate to the nuclear membrane whether cytoplasmic or nuclear localized. Thus, the predicted beta-barrel domain of 5-lipoxygenase may function like the C2 domain within protein kinase C and cytosolic phospholipase A(2) with unique determinants that direct its localization to the nuclear envelope.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11042185     DOI: 10.1074/jbc.M008203200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Location, location, location: compartmentalization of early events in leukotriene biosynthesis.

Authors:  Marcia E Newcomer; Nathaniel C Gilbert
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

3.  Membrane-dependent Activities of Human 15-LOX-2 and Its Murine Counterpart: IMPLICATIONS FOR MURINE MODELS OF ATHEROSCLEROSIS.

Authors:  Gunes Bender; Erin E Schexnaydre; Robert C Murphy; Charis Uhlson; Marcia E Newcomer
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

Review 4.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

5.  Improving protein crystal quality by selective removal of a Ca(2+)-dependent membrane-insertion loop.

Authors:  David B Neau; Nathaniel C Gilbert; Sue G Bartlett; Adam Dassey; Marcia E Newcomer
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-10-24

6.  Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase.

Authors:  Yury I Miller; Dorothy S Worrall; Colin D Funk; James R Feramisco; Joseph L Witztum
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

7.  5-Lipoxygenase: mechanisms of regulation.

Authors:  Olof Rådmark; Bengt Samuelsson
Journal:  J Lipid Res       Date:  2008-11-05       Impact factor: 5.922

8.  A covalent linker allows for membrane targeting of an oxylipin biosynthetic complex.

Authors:  Nathaniel C Gilbert; Marc Niebuhr; Hiro Tsuruta; Tee Bordelon; Oswin Ridderbusch; Adam Dassey; Alan R Brash; Sue G Bartlett; Marcia E Newcomer
Journal:  Biochemistry       Date:  2008-09-12       Impact factor: 3.162

9.  Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo.

Authors:  Christian Feisst; Carlo Pergola; Marija Rakonjac; Antonietta Rossi; Andreas Koeberle; Gabriele Dodt; Marika Hoffmann; Christina Hoernig; Lutz Fischer; Dieter Steinhilber; Lutz Franke; Gisbert Schneider; Olof Rådmark; Lidia Sautebin; Oliver Werz
Journal:  Cell Mol Life Sci       Date:  2009-07-05       Impact factor: 9.261

10.  Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.

Authors:  Yong Tang; Man-Tzu Wang; Yakun Chen; Dianer Yang; Mingxin Che; Kenneth V Honn; Gregory D Akers; Stephen R Johnson; Daotai Nie
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.